Dual PD-1 and VEGF blockade in oncogene-negative NSCLC: where do we stand?
Mené en Chine sur 642 patients atteints d'un cancer du poumon non à petites cellules non épidermoïde de stade localement avancé ou métastatique (âge : 18-75 ans ; durée médiane de suivi : 23,4 mois), cet essai multicentrique de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout de serplulimab (un anti-PD-1) avec ou sans HLX04 (un biosimilaire du bévacizumab) à une chimiothérapie de première ligne
First-line anti-PD-1 or anti-PD-L1 therapy in combination with platinum-doublet chemotherapy is the standard of care for metastatic driver mutation-negative non-small-cell lung cancer (NSCLC). However, only a small proportion of these patients have long-term survival benefits.1 Abnormal tumour vasculature can cause perfusion restriction, hypoxia, and acidosis within the tumour microenvironment and triggers immunosuppression by impeding infiltration of immune effector cells. Theoretically, antiangiogenic agents could normalise tumour vasculature, improve blood perfusion and oxygenation, which creates a more favourable tumour microenvironment for immunotherapy. Although anti-VEGF agents have improved survival outcomes when combined with chemotherapy, the additive benefit of anti-VEGF agents to chemotherapy–immune checkpoint inhibitor combinations remains controversial.
The Lancet Respiratory Medicine , commentaire, 2025